Description
Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Baricitinib is indicated for treating adults with moderate to severe rheumatoid arthritis who have not responded well enough to or could not tolerate at least one tumor necrosis factor antagonist.